AsianScientist (May 20, 2014) – WuXi PharmaTech Inc. has completed construction of a biologics biosafety facility in Suzhou. This is the third building project to be announced in three weeks, following the Changzhou and Philadelphia manufacturing sites.
The Suzhou facility consists of 38,000 square feet of laboratories and support areas in a building adjacent to WuXi’s GLP preclinical drug safety facility. Operations will begin after validations are completed this summer. Service offerings will include clinical and commercial lot release programs, viral clearance testing, and virus and molecular-based safety detection services for Chinese and multinational customers.
The new services will expand WuXi’s already broad, integrated platform of biologics services. In the United States, WuXi offers biosafety testing services such as viral clearance validation and lot release and stability testing. In China, the company’s services include drug discovery, cell-line engineering and construction, bioanalytical services and cGMP drug-substance and drug-product manufacturing for clinical trials.
“WuXi’s expanding capabilities help our customers advance their biologic product candidates through development more quickly and cost-effectively,” said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech. “By investing in capabilities that address our customers’ needs, we have become a leading biologics solution provider.”
——-
Source: WuXi AppTec.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.
